Tuesday, January 12, 2021 6:37:11 AM
Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.
LEXINGTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is capable of detecting the multiple variants of the SARS-CoV-2 virus most recently identified in the United Kingdom, South Africa, and the United States.
“As new strains of the COVID-19 virus emerge, it is critical that we ensure our technology continues to be an effective diagnostic solution during the ongoing pandemic,” said T2 Biosystems’ President and CEO, John Sperzel. “I’m proud that we can confidently say, after extensive analysis, that our T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent, can continue to help impact lives by detecting multiple variants of the SARS-CoV-2 virus.”
Both the variants identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351) contain multiple mutations, most reflected in the S gene, which encodes the spike protein. To confirm that the T2SARS-CoV-2 Panel would detect these variants and other potential mutations of SARS-CoV-2 viruses, an in silico analysis was performed using genome sequences available in the National Center for Biotechnology Information (NCBI) nucleotide database and GISAID database.
Over 42,000 genome sequences for SARS-CoV-2 were evaluated for alignment with primer and probe sequences from T2SARS-CoV-2 Panel. This analysis demonstrated that the T2SARS-CoV-2 Panel should detect 99.99% of all SARS-CoV-2 viruses based on sequence alignments. A specific analysis of sequences for B.1.1.7 and B.1.351 variants confirmed that the T2SARS-CoV-2 Panel should be able to detect these variants.
The T2SARS-CoV-2 Panel provides results in under two hours utilizing an upper respiratory swab sample. The test runs on the Company’s FDA-cleared and fully-automated T2Dx® Instrument, which is capable of performing seven tests simultaneously and up to sixty samples per day.
The same T2Dx Instrument is also capable of running the FDA-cleared T2Bacteria® Panel and T2Candida® Panel. These panels are the only FDA-cleared assays for the detection of sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results. By providing quicker results, the panels enable clinicians to target therapy faster for their patients suspected of sepsis, often before the second dose of antimicrobial medicine is administered, leading to better patient outcomes, improved antimicrobial stewardship, and reductions in length of stay in the hospital.
These additional panels remain especially clinically relevant during the pandemic, as data suggests that the COVID-19 virus can lead to sepsis, and death.
https://www.globenewswire.com/news-release/2021/01/11/2156669/0/en/T2-Biosystems-T2SARS-CoV-2-Panel-Proves-Effective-Amid-Global-Rise-in-Variants-of-the-SARS-CoV-2-Virus.html
MegaDeath, changed due to circumstances of COVID-19 pandemic.
Recent TTOO News
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor • GlobeNewswire Inc. • 12/18/2024 02:00:00 PM
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally • GlobeNewswire Inc. • 12/17/2024 02:00:00 PM
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. • GlobeNewswire Inc. • 12/16/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 02:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/09/2024 02:02:59 PM
- T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens • GlobeNewswire Inc. • 12/09/2024 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/20/2024 09:45:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/20/2024 09:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 02:54:00 PM
- T2 Biosystems Announces Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/14/2024 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 08:49:19 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/14/2024 08:38:45 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/08/2024 10:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 02:30:28 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/07/2024 02:02:19 AM
- T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 • GlobeNewswire Inc. • 11/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 08:59:59 PM
- T2 Biosystems to Host Business Update Call on October 10, 2024 • GlobeNewswire Inc. • 10/08/2024 08:05:00 PM
- T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform • GlobeNewswire Inc. • 10/08/2024 01:00:00 PM
- T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens • GlobeNewswire Inc. • 10/07/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 01:00:32 PM
- T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 10/07/2024 01:00:00 PM
- T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture • GlobeNewswire Inc. • 09/23/2024 01:00:00 PM
- T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union • GlobeNewswire Inc. • 09/20/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:59:59 PM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM